Poziotinib (HM781-36B)

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Poziotinib (HM781-36B)	Purity：98% min
CAS NO：1092364-38-9	Solubility：DMSO : 50 mg/mL (101.76 mM; Need ultrasonic)
Molecular Formula：C₂₃H₂₁Cl₂FN₄O₃	Package：Packaging according to customer requirements
Molecular Weight：491.34	Storage：Store at -20℃

Quality control

Remarks

Poziotinib , also known as HM781-36B and NOV120101, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity. HM781-36B irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. EGFRs, cell surface receptor tyrosine kinases, are often upregulated in a variety of cancer cell types and play key roles in cellular proliferation and survival.

HER2 Inhibitors Related Products:

Mubritinib; Tucatinib; Canertinib; Canertinib dihydrochloride; Lapatinib; Lapatinib ditosylate; Afatinib (BIBW2992); Afatinib (BIBW2992) Dimaleate; CUDC-101; TAK-285; Sapitinib

References

[1]. Nam HJ, et al. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett. 2011 Mar 28;302(2):155-65.

[2]. Cha MY, et al. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.

[3]. Kang MH, et al. Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. Cancer Res Treat. 2015 Mar 5.